2. Academic Validation
  3. Ibalizumab: First Global Approval

Ibalizumab: First Global Approval

  • Drugs. 2018 May;78(7):781-785. doi: 10.1007/s40265-018-0907-5.
Anthony Markham 1
Affiliations

Affiliation

  • 1 Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.
PMID: 29675744 DOI: 10.1007/s40265-018-0907-5
Abstract

TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 Infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 Inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99028
    99.52%, Anti-CD4 Monoclonal Antibody
    HIV